Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2005

View Archived Issues

Nalfurafine hydrochloride reduces scratching in a possible murine model of pruritis

Recent patents cover novel treatments for neurodegenerative disorders

New treatments for psychosis and depression in early development

Novel diagnostic agents disclosed by Amersham

MMP inhibitors for arthritis emerge from Japan Tobacco R&D

CYC-10268 targets macrophage survival in vitro

ELB-353: in vitro and in vivo data demonstrate potential for asthma/COPD

MEK1 inhibitor achieves superior results in a murine colon cancer model

TTI-237: A novel, small-molecule tubulin inhibitor with novel mechanism of action

Mycophenolate mofetil shows promise in the treatment of inflammatory eye disease

Gentium updates status of defibrotide program

Enrollment completed in phase II study of MN-001 for asthma

Phase III Veronate trial recommended to continue by DSMB

Novartis and Alnylam establish major RNAi alliance

Avax files IND for phase I/II NSCLC study of AC Vaccine Therapeutic

ACTIVE W arm discontinued in clopidogrel program

Centocor selects new target in Morphosys collaboration

huN901-DM1 enters clinical testing for multiple myeloma

Celera Diagnostics and Merck & Co extend Alzheimer's collaboration

Genentech targets Lucentis BLA filing for December

WHO urges monitoring of antimalarials for effectiveness

Ataciguat - a promising therapeutic option for cardiovascular complications in diabetic patients

In vivo models validate superior efficacy of BAY-59-7939 over fondaparinux

AVE-0118 is safe in experimental CHF

Novel pathway-selective LXR modulator developed

Novel HCV-NS3 protease inhibitor enters clinical development

Preclinical studies evaluate the antinociceptive effects of TQ-1015

Dronedarone reduces the ventricular rate of patients with atrial fibrillation

AZD-6140 shows efficacy in inhibiting platelet aggregation in patients with atherosclerosis

Swiss approval for once-monthly Bonviva

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...